An overview of the genetics of substance use disorders

Current Psychiatry Reports

Volumn 8, Issue 2, 2006, Pages 133-143

  Lachman, H M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE RECEPTOR; METHADONE; OPIATE RECEPTOR;

ALCOHOLISM; ALLELE; DRUG DEPENDENCE; ENVIRONMENTAL FACTOR; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HUMAN; OPIATE ADDICTION; PHENOTYPE; QUANTITATIVE TRAIT LOCUS; REVIEW; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TWINS; VARIABLE NUMBER OF TANDEM REPEAT;

ALLELES; CATECHOL O-METHYLTRANSFERASE; DOPAMINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MINISATELLITE REPEATS; NUCLEUS ACCUMBENS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, OPIOID, MU; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 33645558987     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0013-3     Document Type: Review

References (71)

1. Goldman D, Oroszi G, Ducci F: The genetics of addictions: uncovering the genes. Nat Rev Genet 2005, 6:521-532.
2. Kreek MJ, Nielsen DA, Butelman ER, Laforge KS: Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neuroscience 2005, 8:1450-1457.
3. Caderet RJ, Yates WR, Troughton E, et al.: Adoption study demonstrating two genetic pathways to drug abuse. Arch Gen Psychiatry 1995, 52:42-52.
4. Pickens SW, Svikis DS, McCue M, LaBuda M: Common genetic mechanisms in alcohol, drug and mental disorder comorbidity. Drug Alcohol Dep 1995, 39:129-138.
5. Tsuang MT, Lyons MJ, Eisen SA, et al.: Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet (Neuropsychiat Genet) 1996, 67:473-477.
6. Bierut LJ, Dinwiddie SH, Begleiter H, et al.: Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry 1998, 55:982-988.
7. Uhl GR: Molecular genetics of substance abuse vulnerability: remarkable recent convergence of genome scan results. Ann NY Acad Sci 2004, 1025:1-13.
8. Grove W, Eckert E, Heston L, et al.: Heritability of substance abuse and antisocial behavior: a study of monozygotic twins reared apart. Biol Psychiatry 1990, 27:1293-1304.
9. van den Bree MB, Johnson EO, Neale MC, Pickens RW: Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend 1998, 52:231-241.
10. Swan GE, Carmelli D, Cardon LR: Heavy consumption of cigarettes, alcohol and coffee in male twins. J Stud Alcohol 1997, 58:182-190.
11. Tsuang MT, Lyons MJ, Meyer JM, et al.: Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psych 1998, 55:967-972.
12. Kendler KS, Jacobson KC, Prescott CA, Neale MC: Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003, 160:687-695.
13. Nesler EJ: Is there a common molecular pathway for addiction? Nat Neurosci 2005, 8:1445-1449.
14. Kosten TA, Ambrosio E: HPA axis function and drug addictive behaviors: insights from studies with Lewis and Fischer 344 inbred rats [review]. Psychoneuroendocrinology 2002, 27:35-69.
15. Brower VG, Fu Y, Matta SG, Sharp BM: Rat strain differences in nicotine self-administration using an unlimited access paradigm. Brain Res 2002, 930:12-20.
16. Merikangas KR, Risch N: Genomic priorities and public health. Science 2003, 302:599-601.
17. Frances H, Le Foll B, Diaz J, et al.: Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice. Neuroreport 2004, 15:2245-2249.
18. Maldonado R, Saiardi A, Valverde O, et al.: Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997, 388:586-589.
19. Matthes HW, Maldonado R, Simonin F, et al.: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383:819-823.
20. Tsai HJ, Kho JY, Shaikh N, et al.: Admixture-matched case-control study: a practical approach for genetic association studies in admixed populations. Hum Genet 2005, 5:1-14.
21. Blum K, Noble EP, Sheridan PJ, et al.: Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1990, 263:2055-2060.
22. Xu K, Liu XH, Nagarajan S, et al.: Relationship of the delta-opioid receptor gene to heroin abuse in a large Chinese case/control sample. Am J Med Genet 2002, 110:45-50.
23. Stober G, Jatzke S, Heils A, et al.: Insertion/deletion variant (-141C Ins/Del) in the 5′ regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder. J Neural Transm 1998, 105:101-109.
24. Parsian A, Cloninger CR, Zhang ZH: Functional variant in the DRD2 receptor promoter region and subtypes of alcoholism. Am J Med Genet 2000, 96:407-411.
25. Li T, Liu X, Zhao J, et al.: Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects. Am J Med Genet 2002, 114:329-335.
26. Xu K, Lichtermann D, Lipsky RH, et al.: Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry 2004, 61:597-606.
27. Gelernter J, Kranzler HR, Satel SL, Rao PA: Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 1994, 11:195-200.
28. Hong CJ, Cheng CY, Shu LR, et al.: Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males. J Neural Transm 2003, 110:345-351.
29. Ujike H, Harano M, Inada T, et al.: Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 2003, 3:242-247.
30. Cubells JF, Zabetian CP: Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl) 2004, 174:463-476.
31. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68.
32. Vandenberg DJ, Miller I, Uhl G, Lachman HM: A high activity COMT allele is associated with substance abuse vulnerability. Am J Med Genet (Neuropsychiat Genet) 1997, 74:439-442.
33. Tiihonen J, Hallikainen T, Lachman HM, et al.: Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry 1999, 4:286-289.
34. Hallikainen T, Lachman H, Saito T, et al.: Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early onset alcoholism associated with severe antisocial behavior. Am J Med Genet 2000, 96:348-352.
35. Horowitz R, Kotler M, Shufman E, et al.: Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 2000, 96:599-603.
36. Li T, Chen CK, Hu X, et al.: Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet 2004, 129:120-124.
37. Wang T, Franke P, Neidt H, et al.: Association study of the low-activity allele of catechol-O-methyltransferase and alcoholism using a family-based approach. Mol Psychiatry 2001, 6:109-111.
38. Ishiguro H, Haruo Shibuya T, Toru M, et al.: Association study between high and low activity polymorphism of catechol-O-methyltransferase gene and alcoholism. Psychiatr Genet 1999, 9:135-138.
39. Duaux E, Gorwood P, Griffon N, et al.: Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol Psychiatry 1999, 3:333-336.
40. Comings DE, Gonzalez N, Wu S, et al.: Homozygosity at the dopamine DRD3 receptor gene in cocaine dependence. Mol Psychiatry 1999, 4:484-487.
41. Li T, Liu X, Zhao J, et al.: Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A) gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects. Am J Med Genet 2002, 114:329-335.
42. Bart G, Kreek MJ, Ott J, et al.: Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005, 30:417-422.
43. Berrettini WH, Ferraro TN, Alexander RC, et al.: Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet 1994, 7:54-58.
44. Bond C, LaForge KS, Tian M, et al.: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998, 95:9608-9613.
45. Szeto CY, Tang NL, Lee DT, Stadlin A: Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 2001, 12:1103-1106.
46. Bart G, Heilig M, LaForge KS, et al.: Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 2004, 9:547-549.
47. Crowley JJ, Oslin DW, Patkar AA, et al.: A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 2003, 13:169-173.
48. Shi J, Hui L, Xu Y, et al.: Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat 2002, 19:459-460.
49. Hernandez-Avila CA, Wand G, Luo X, et al.: Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet (Neuropsychiatr Genet) 2003, 118:60-65.
50. Wand GS, McCaul M, Yang X, et al.: The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002, 26:106-114.
51. Oslin DW, Berrettini W, Kranzler HR, et al.: A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28:1546-1552.
52. Yuferov V, Fussell D, LaForge KS, et al.: Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 2004, 14:793-804.
53. Mayer P, Rochlitz H, Rauch E, et al.: Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport 1997, 8:2547-2550.
54. Xu K, Liu XH, Nagarajan S, et al.: Relationship of the delta-opioid receptor gene to heroin abuse in a large Chinese case/control sample. Am J Med Genet 2002, 110:45-50.
55. Comings DE, Blake H, Dietz G, et al.: The proenkephalin gene (PENK) and opioid dependence. Neuroreport 1999, 10:1133-1135.
56. Zimprich A, Kraus J, Woltje M, et al.: An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem 2000, 74:472-477.
57. Chen AC, LaForge KS, Ho A, et al.: Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet 2002, 114:429-435.
58. Ray R, Doyle GA, Crowley JJ, et al.: A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatr Genet 2005, 15:295-298.
59. Edenberg HJ: The Collaborative Study on the Genetics of Alcoholism: an update. Alcohol Res Health 2002, 26:214-218.
60. Li MD, Ma JZ, Cheng R, et al.: A genome-wide scan to identify loci for smoking rate in the Framingham Heart Study population. BMC Genet 2003, 4 Suppl 1:S103.
61. Gelernter J, Panhuysen C, Weiss R, et al.: Genomewide linkage scan for cocaine dependence and related traits: significant linkages for a cocaine-related trait and cocaine-induced paranoia. Am J Med Genet (Neuropsychiat Genet) 2005, 136:45-52.
62. Edenberg HJ, Dick DM, Xuei X, et al.: Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet 2004, 74:705-714.
63. Covault J, Gelernter J, Hesselbrock V, et al.: Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet (Neuropsychiat Genet) 2004, 129:104-109.
64. Beuten J, Ma JZ, Payne TJ, et al.: Single- and multilocus allelic variants within the GABA(B) receptor subunit 2 (GABAB2) gene are significantly associated with nicotine dependence. Am J Hum Genet 2005, 76:859-864.
65. Li MD, Beuten J, Ma JZ, et al.: Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 2005, 14:1211-1219.
66. Uhl GR, Liu QR, Walther D, et al.: Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet 2001, 69:1290-1300.
67. Liu QR, Drgon T, Walther D, et al.: Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc Natl Acad Sci U S A 2005, 102:11864-11869.
68. Grossman A: Brain opiates and neuroendocrine function. Clin Endocrinol Metab 1983, 12:725-746.
69. Coventry TL, Jessop DS, Finn DP, et al.: Endomorphins and activation of the hypothalamo-pituitary-adrenal axis. J Endocrinol 2001, 169:185-193.
70. Shirayama Y, Ishida H, Iwata M, et al.: Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 2004, 90:1258-1268.
71. Tseng RJ, Padgett DA, Dhabhar FS, et al.: Stress-induced modulation of NK activity during influenza viral infection: role of glucocorticoids and opioids. Brain Behav Immun 2005, 19:153-164.